

## **Nevrargenics participates in the first post-COVID Treatment Research Initiative to Cure ALS workshop in the Netherlands**

### **Date**

**1 October 2022**

Nevrargenics Ltd, the UK biotech company focusing on developing novel small molecule drugs that modulate the retinoic acid receptors to treat neurodegenerative and other diseases, is pleased to announce that it was invited to participate at the TRICALS workshop taking place at Schiphol, Netherlands, on 28 & 29 September 2022.

The Treatment Research Initiative to Cure ALS or TRICALS, is the largest European research initiative to find a cure for ALS to date. 48 top research centres in 16 countries have joined hands with patient organisations and fundraisers to reach its one goal: find effective treatments for ALS. TRICALS is the world's largest network of specialist ALS centers.

More information on TRICALS can be found here <https://www.tricals.org/>

### **Notes**

ALS, or Amyotrophic Lateral Sclerosis (also referred to as Motor Neurone Disease) is a neurodegenerative disease affecting motorneurons; it is fatal, characterised by progressive muscular atrophy; it is accompanied with cognitive impairment in around half of patients and there are no effective treatments.

ALS is an orphan indication.

For more information, contact:

Prof Andy Whiting, CEO  
Nevrargenics Ltd  
Ouse House, Unit 31A  
Mandale Park  
Belmont Industrial Estate  
Durham DH1 1TT  
U.K.

[info@nevrargenics.com](mailto:info@nevrargenics.com)

[www.nevrargenics.com](http://www.nevrargenics.com)

Nevrargenics Ltd is a UK-based biotech company specialising in the discovery and development of novel medicines for the treatment of neurodegenerative disease, such as Alzheimer's, Parkinson's, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and other neurological and psychiatric diseases.